{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants who achieved a best response of either CR or PR per Grever and colleagues. CR: Near normalization of peripheral blood counts: hemoglobin \\>11 g/dL (without transfusion); platelets \\>100 000/μL; absolute neutrophil count \\>1500/μL. Regression of splenomegaly on physical examination. Absence of morphologic evidence of HCL on both the peripheral blood smear and the bone marrow examination. PR: PR required near normalization of the peripheral blood count (as in CR) with a minimum of 50% improvement in organomegaly and bone marrow biopsy infiltration with HCL.","groups":[{"description":"Participants with Relapsed/Refractory hairy cell leukemia received the following treatment during the study: Lymphodepletion chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3). A single IV infusion of brexucabtagene autoleucel at target dose of 2 × 10\\^6 anti-CD19 CAR T cells/kg on Day 0.","id":"OG000","title":"Substudy D (Relapsed/Refractory Hairy Cell Leukemia): Brexucabtagene Autoleucel"}],"populationDescription":"Data cannot be reported for this outcome measure because substudy D was terminated before the central committee could be formed hence central assessment was not performed. There are no plans to analyze these data in the future.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Substudy D: ORR Determined by Central Assessment Per the Response Criteria Described by Grever and Colleagues","type":"PRIMARY"}